Zobrazeno 81 - 90
of 13 442
pro vyhledávání: ''
Publikováno v:
Current Vascular Pharmacology. 19:390-397
Background: Statins are the mainstay of treatment for low-density lipoprotein cholesterol (LDL-C) lowering, however, some patients cannot tolerate statins because of adverse effects. Ezetimibe and proprotein convertase subtilisin/kexin type 9 inhibit
Autor:
Yingchun Luo, Yue Wu, Xuejie Han, Dingyu Wang, Danghui Sun, Yun Zhang, Shiqi Zhao, Song Zhang, Yunlong Gao, Yongtai Gong, Xinbo Zhao, Yun Zhou, Dan Li, Yue Li, Wanlan Bo, Xiaozhen Zhuo, Hui Yu, Jiawei Zhang, Zixi Wang, Bolin Li, Desen Liang, Wei Xu, Xuexin Jin, Guangjin Qu
Publikováno v:
Cardiovascular Research. 118:785-797
Aims Aging is the most significant contributor to the increasing prevalence of atrial fibrillation (AF). The gut microbiota dysbiosis is involved in age-related diseases. However, whether the aged-associated dysbiosis contributes to age-related AF is
Autor:
Craig M Jackson
Publikováno v:
Journal of Thrombosis and Thrombolysis. 52:371-378
The evolution of our understanding of the formation of thrombin from the postulated thrombokinase of Morawitz to activated Factor X and prothrombinase occurred during a period of nearly 100 years. During this time structure–function relationships h
Autor:
Kenneth G. Mann
Publikováno v:
Journal of Thrombosis and Thrombolysis. 52:379-382
This review is a brief summary of the history of the development of the Prothrombinase complex paradigm and its incorporation into the "extrinsic pathway". It summarizes my laboratory's research from 1968 to 2012 and identifies many of the key player
Autor:
Shobi Mathew, Phillip D. Levy, Rafael Fridman, Candace D. McNaughton, Michael J. Twiner, John M. Flack, Brian Reed, Cesar A. Romero, Benjamin D. Wasinski, Rachelle Dawood, Aaron Brody, Oscar A. Carretero
Publikováno v:
The Journal of Clinical Hypertension
Angiotensin-converting enzyme inhibitors (ACEi) are part of the indicated treatment in hypertensive African Americans. ACEi have blood pressure-independent effects that may make them preferred for certain patients. We aimed to evaluate the impact of
Autor:
Sonali Narain, Prashant Malhotra, Ona Bloom, Sanjaya K. Satapathy, David Hirschwerk, Alice S. Chau, Negin Hajizadeh, Michael Qiu, Matthew D. Taylor, Naomi I Maria, Dimitre G. Stefanov, Audrey Liu, Martin Lesser, Jennifer Cookingham, Blanka Kaplan, Cristina Sison, Andrew G. Weber, Stuart L. Cohen, Galina Marder
Publikováno v:
Chest
Background Cytokine storm is a marker of COVID-19 illness severity and increased mortality. Immunomodulatory treatments have been repurposed to improve mortality outcomes. Research Question To identify if immunomodulatory therapies improve survival i
Publikováno v:
Journal of Atherosclerosis and Thrombosis
Abdominal aortic aneurysm (AAA) is a chronic inflammatory degenerative aortic disease, which particularly affects older people. Nucleotide-binding oligomerization domain-like receptor family protein 3 (NLRP3) inflammasome is a multi-protein complex a
Autor:
Areti Pagiantza, Ioannis Farmakis, Stefanos Zafeiropoulos, Ioannis Doundoulakis, Haralambos Karvounis, George Giannakoulas, Christina Antza
Publikováno v:
Journal of Cardiovascular Pharmacology. 77:397-407
Lipoprotein(a) [Lp(a)] is a cardiovascular factor, for which there is no approved specific lowering treatment. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have been shown to have lowering effects on Lp(a). Aim of this systematic
Publikováno v:
Cardiovasc Res
Ageing is the most significant contributor to the increasing prevalence of atrial fibrillation (AF). The gut microbiota dysbiosis is involved in age-related diseases. However, whether the aged-associated dysbiosis contributes to age-related AF is sti
Autor:
Hwee Tat Tan, Stephrene Seok Wei Chan, Yew Woon Chia, Shu Ping Lim, Chwee Fang Bok, Mui Kia Ang, Christina Lai Lin Sum, Shiun Woei Wong, Gek Hsiang Lim, David C. Lye, Dheepa Christopher, Kollengode Ramanathan, Jia Yan Lim, Ponnudurai Kuperan, Barnaby Edward Young, Kiat Hoe Ong, Rui Min Lee, Bingwen Eugene Fan, Soon Lee Lau
Publikováno v:
Journal of Thrombosis and Thrombolysis
Severe COVID-19 patients demonstrate hypercoagulability, necessitating thromboprophylaxis. However, less is known about the haemostatic profile in mild COVID-19 patients. We performed an age and gender-matched prospective study of 10 severe and 10 mi